Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

17.39 +0.16 (+0.93%)

Streaming Delayed Price Updated: 9:51 AM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products

July 27, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1

July 26, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗

July 14, 2023

Via Benzinga

Disney Considers Different Strategies For Star India, Broadcom Wins Conditional European Approval For VMware Deal, Google Deprioritizes Gen Z Chatbot App: Today's Top Stories ↗

July 12, 2023

Wall Street Journal

Via Benzinga

Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement ↗

July 12, 2023

Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily

Via Benzinga

Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration ↗

July 08, 2023

F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...

Via Talk Markets

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

June 25, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity ↗

June 21, 2023

The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients...

Via Benzinga

Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis ↗

June 21, 2023

The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...

Via Benzinga

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

June 20, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

3 AI Stocks That Could Skyrocket Your Wealth ↗

June 20, 2023

AI is poised to greatly increase the top and bottom lines of many companies, making many AI stocks very attractive at this point.

Via InvestorPlace

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

June 15, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet

June 15, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

June 15, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting ↗

June 13, 2023

Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy...

Via Benzinga

3 Stocks That Could Skyrocket by This Time Next Summer ↗

June 08, 2023

The best stocks to skyrocket in June have all done well in 2023 and over the past year. They definitely ought to be on your watchlist.

Via InvestorPlace

Why Shares of Innate Pharma Jumped Thursday ↗

June 08, 2023

The company's collaboration agreement with Sanofi could soon pay off.

Via The Motley Fool

Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress

May 26, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

May 25, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq ↗

May 19, 2023

The FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to

Via Benzinga

U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

May 16, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Moves Out From Licensing Agreement With Theravance Biopharma ↗

May 11, 2023

In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'...

Via Benzinga

Earnings Scheduled For May 11, 2023 ↗

May 11, 2023

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...

Via Benzinga

Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues ↗

May 11, 2023

Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its

Via Benzinga

Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook

May 11, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

April 27, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations

April 26, 2023

From Corza Medical Inc.

Via GlobeNewswire

Cannabis Movers & Shakers: Latest Appointments From Khiron, MariMed, Equilibria & More ↗

April 25, 2023

Equilibria Strengthens Women's Wellness With New CSO

Via Benzinga

Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday ↗

April 25, 2023

The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.

Via The Motley Fool

This Supercharged Dividend King Stock Might Soon Run Out of Steam ↗

April 25, 2023

Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.